An Open-label Study Evaluating the Pharmacokinetics and Tolerability of [Vortioxetine] Lu AA21004 in Connection With Multiple Oral Dosing of [Vortioxetine] Lu AA21004 in Child and Adolescent Patients With a DSM-IV Diagnosis of Depressive or Anxiety Disorder
Phase of Trial: Phase II
Latest Information Update: 21 Mar 2017
At a glance
- Drugs Vortioxetine (Primary)
- Indications Anxiety disorders; Depressive disorders
- Focus Pharmacokinetics
- Sponsors Lundbeck A/S
- 26 Oct 2015 According to ClinicalTrial.gov record, the primary endpoints have been amended and hence the trial focus has changed from PK and AR to only PK
- 26 Oct 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 03 Mar 2015 Planned End Date changed from 1 Dec 2014 to 1 Jun 2015, according to ClinicalTrials.gov record.